

F A I R V I E W

■ C A P I T A L ■



Elements of Excellence Netcast

Recorded June 9, 2010

Guest:

Rick Charpie, Managing General Partner – Ampersand Ventures

[Rick Charpie](#) has nearly 30 years of private equity experience. He joined Ampersand's predecessor in 1980 and led its activities beginning in 1983. Rick founded the firm in 1988 by structuring its spinoff from PaineWebber. He's served as a director of more than 35 companies and Chairman of more than ten. He holds an M.S. in Physics and a Ph.D. in Economics and Finance, both from MIT.

Current board seats:

CoreLab Partners, Endeca, K-TEK, RAND Worldwide, Talecris Biotherapeutics

Prior board seats include:

ADFlex, Cyclis, Medifacts, Moldflow, Precision Pharma Services, TriPath Imaging



[Ampersand Ventures](#) traces its lineage to the early days of the private equity industry. Organized in 1969 as an internal technology-focused venture capital investment activity at PaineWebber, Ampersand was spun off in 1988. Today, Ampersand is a Boston-based, middle-market private equity firm focused on the Healthcare and Industrial sectors. The firm targets later stage growth equity opportunities, where they can be the first institutional investor. The team's unique blend of private equity and operating skills positions them to take an active teamwork approach to construct distinctive portfolios and drive long-term performance.



[Talecris Biotherapeutics](#) is a global biotherapeutic and biotechnology company based in Research Triangle Park, N.C. that discovers, develops and produces critical care treatments for people with life-threatening disorders in a [variety of therapeutic areas](#).

[IPO in September 2009](#)

[Acquisition by Grifols for \\$3.4 billion in June 2010](#)

Founded in 1994 and headquartered in West Hartford, Connecticut, [Fairview Capital Partners, Inc.](#) is an independent firm that provides investment management services to the Fairview family of venture capital and private equity funds-of-funds. Fairview sponsors funds that focus on highly-regarded venture capital and private equity partnerships, as well as funds that focus on emerging and the next generation of leading managers.